Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $13.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective boosted by B. Riley Financial from $11.00 to $13.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Piper Sandler began coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. Truist Financial set a $12.00 target price on shares of Perspective Therapeutics in a report on Tuesday. UBS Group increased their target price on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright boosted their price target on Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Royal Bank Of Canada decreased their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Trading Down 3.3%

CATX opened at $4.45 on Wednesday. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16. The business’s 50 day moving average is $4.37 and its two-hundred day moving average is $3.44. The company has a quick ratio of 8.66, a current ratio of 5.17 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The firm had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. Analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently modified their holdings of CATX. Los Angeles Capital Management LLC purchased a new stake in Perspective Therapeutics in the 2nd quarter worth approximately $61,000. Geode Capital Management LLC increased its position in Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after purchasing an additional 405,612 shares during the period. Walleye Capital LLC lifted its position in Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after buying an additional 60,019 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: UBS raised its price target for CATX to $8.00, signaling increased upside from current levels and giving investors a higher valuation reference. UBS Group Raises Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $8.00
• Positive Sentiment: B. Riley Financial analyst says CATX stock price is expected to rise, which can attract momentum buying and support higher valuations. Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on CATX, reinforcing buy-side sentiment from another boutique/specialist analyst. Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
• Positive Sentiment: Brookline Capital Markets materially raised its FY2026 and quarter-by-quarter EPS estimates (still negative EPS, but less severe), suggesting improving expectations for the company’s financial trajectory. This reduces downside risk from prior forecasts. (Market data / analyst note)
• Positive Sentiment: BTIG initiated/maintained a Buy rating on CATX, adding further institutional buy-side support. Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Buy Rating from BTIG Research
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX, which can add short-term pressure and offset some of the positive analyst actions. Royal Bank Of Canada Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.